About oncolytics bio - ONCY
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
ONCY At a Glance
Oncolytics Biotech, Inc.
322–11th Avenue Southwest
Calgary, Alberta T2R 0C5
| Phone | 1-403-670-7377 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -23,146,634.47 | |
| Sector | Health Technology | Employees | 28 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ONCY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 17.577 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.361 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.012 |
ONCY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -826,665.517 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ONCY Liquidity
| Current Ratio | 2.823 |
| Quick Ratio | 2.823 |
| Cash Ratio | 2.384 |
ONCY Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -106.479 |
| Return on Equity | -184.705 |
| Return on Total Capital | -472.392 |
| Return on Invested Capital | -179.22 |
ONCY Capital Structure
| Total Debt to Total Equity | 17.784 |
| Total Debt to Total Capital | 15.099 |
| Total Debt to Total Assets | 5.271 |
| Long-Term Debt to Equity | 13.154 |
| Long-Term Debt to Total Capital | 11.168 |